• Age-related macular degeneration (AMD) is a progressive chronic disease of the central retina accounting for 8.7% of all blindness worldwide1.
• Early AMD patients exhibit moderate to severe impairment of dark adaptation (DA) even in the absence of visual acuity loss4–6.
• A test to probe rod function in dark adaptation can be used as a clinical outcome measure in studies tracking the progression of AMD, or more practically, a diagnostic tool targeting the identification of early AMD4.
• A patient’s rod function can be easily examined with Heru’s dark adaptation test which is billable to insurance (CPT 92284) and co-billable with visual fields, OCT and/or office visits.
By Greg Caldwell, OD, FAAO There are times in the life of every practitioner when making a diagnosis can be…
Heru Wins Prestigious CES Innovation Award for 2nd Consecutive Year with Expanded, Multimodal Platform MIAMI, FL (November 17, 2022) — Today,…
Heru Continues to Revolutionize Vision Care, Surpassing Clinical Milestone of 100,000 Eyes Examined MIAMI--November 14, 2022, Heru Inc. announced that…
Shine a Spotlight on AMD: 5 Reasons to Screen Your Patients by Milan Lockhart, OD As our patient's age, their eyes…
Miami, FL (October 31, 2022) – Today, Heru announced several key executive appointments across its leadership team and board of…
By Greg Caldwell, OD, FAAO 196 million people worldwide are impacted by age-related macular degeneration (AMD), with as many as…